SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Microcide Pharmaceuticals (MCDE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Chavez who wrote (12)2/6/1997 6:46:00 PM
From: scaram(o)uche   of 186
 
Microcide Achieves Milestone in Pfizer Collaboration

MOUNTAIN VIEW, Calif., Feb. 6 /PRNewswire/ -- Microcide
Pharmaceuticals Inc today announced that it has achieved the first
milestone under its Essential Genes collaboration with Pfizer Inc.,
triggering a $1 million payment which will be made to Microcide in
March, 1997. This milestone relates to the identification, validation
and sequencing of an agreed upon number of bacterial essential genes,
for use as targets in screening for new classes of antibiotics.

In March 1996, Microcide and Pfizer entered into a research
collaboration which focuses on identifying genes that are essential to
in-vitro bacterial viability (Essential Genes) and utilizes these gene
targets in Microcide's high-throughput screening systems to identify
active compounds for further development.

Microcide is a biopharmaceutical company founded to discover, develop
and commercialize novel antibiotics for the treatment of serious
bacterial infections. The Company's research programs address the
growing problem of bacterial drug resistance through two principal
themes: (i) Targeted Antibiotics, which focuses on developing novel
antibiotics and antibiotic potentiators to overcome bacterial
resistance mechanisms, and (ii) Targeted Genomics, which utilizes
bacterial genetics to discover new classes of antibiotics and other
novel treatments for bacterial diseases. Microcide has also extended
its functional genomics technology platform into an antifungal program
designed to discover broad spectrum fungicidal agents. SOURCE
Microcide Pharmaceuticals Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News